| 1434 |
National Cancer Institute |
Html |
en |
Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia. |
| CLL | 0.563454 |
| German CLL Study | 0.551069 |
| monoclonal B-cell lymphocytosis | 0.528403 |
| Engl J Med | 0.555252 |
| trial | 0.525679 |
| leukemia group | 0.552678 |
| M. Prolymphocytic leukemia | 0.545972 |
| Routine chronic administration | 0.534661 |
| lymphocytic leukemia patients | 0.591222 |
| Leukemia group B. | 0.542105 |
| CLL Study Group | 0.54078 |
| cyclophosphamide | 0.529502 |
| Byrd JC | 0.527428 |
| Keating MJ | 0.535835 |
| advanced chronic | 0.539233 |
| patients | 0.592663 |
| Lymphocytic Leukemia Study | 0.593872 |
| T-cell prolymphocytic leukemia | 0.546745 |
| refractory high-risk chronic | 0.534243 |
| refractory chronic | 0.528565 |
| Adult Leukemia Group | 0.542021 |
| Leuk Lymphoma | 0.531402 |
| Lymphocytic Leukemia section | 0.595648 |
| fludarabine | 0.547348 |
| alemtuzumab versus fludarabine | 0.527105 |
|
| untreated B chronic | 0.530625 |
| et al. | 0.648755 |
| treatment | 0.535273 |
| small lymphocytic lymphoma | 0.590269 |
| French Cooperative Group | 0.528743 |
| German Chronic Lymphocytic | 0.583925 |
| Relapsed Chronic Lymphocytic | 0.579501 |
| acute myeloid leukemia | 0.53754 |
| stem cell | 0.529413 |
| Leukemia Study Group | 0.55235 |
| rituximab | 0.530116 |
| fludarabine-refractory B-cell chronic | 0.53547 |
| CLL therapy | 0.52689 |
| chronic lymphoid leukemia | 0.573599 |
| CLL Study Group. | 0.526303 |
| Abstract | 0.627578 |
| therapy | 0.53011 |
| Clin Oncol | 0.713099 |
| hairy cell leukemia | 0.553353 |
| blood | 0.56117 |
| chronic lymphocytic leukemia | 0.965039 |
| chronic lymphocytic leukaemia | 0.705583 |
| previously untreated patients | 0.578343 |
| allogeneic stem cell | 0.525551 |
|
CLICK HERE |
| 1870 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario. |
| germ-cell tumors | 0.421459 |
| germ-cell tumors with | 0.411803 |
| Obstet Gynecol | 0.406415 |
| ovarian germ | 0.634072 |
| malignant germ | 0.435096 |
| endodermal sinus tumor | 0.403615 |
| cell tumors treated | 0.404749 |
| Liao SY | 0.410388 |
| Adjuvant therapy | 0.410358 |
| Gershenson DM | 0.467949 |
| Current therapy | 0.403318 |
| Williams SD | 0.494559 |
| tumores malignos mixtos | 0.404882 |
| Hacker NF | 0.402853 |
| Instituto Nacional | 0.403668 |
| high-dose chemotherapy | 0.403104 |
| or etoposide | 0.404727 |
| DiSaia PJ | 0.408704 |
| Moore DH | 0.407371 |
| University Medical Center | 0.403543 |
| quimioterapia postoperatoria | 0.403765 |
| Gynecol Oncol | 0.453558 |
| pacientes jóvenes | 0.408368 |
| lavados peritoneales | 0.410402 |
| New York University | 0.403494 |
|
| Icb Tumor | 0.403092 |
| gynecologic oncology group | 0.703201 |
| Blessing JA | 0.51199 |
| Birch R | 0.404259 |
| estadio iv | 0.424378 |
| Einhorn LH | 0.40484 |
| Dembo AJ | 0.402909 |
| estadio ia | 0.408575 |
| ovary with | 0.410468 |
| Morris M | 0.407706 |
| with advanced germ | 0.403782 |
| IIIa Tumor | 0.403067 |
| York University Medical | 0.403528 |
| Intern Med | 0.411687 |
| second-look laparotomy | 0.431921 |
| Clin Oncol | 0.539728 |
| estadio iii | 0.41476 |
| cell tumors using | 0.405334 |
| tumor macroscópico | 0.402814 |
| Oncology Group Study | 0.403519 |
| germ cell tumors | 0.985883 |
| histerectomÃa abdominal | 0.412918 |
| Cangir A | 0.408111 |
| cell tumors with | 0.436879 |
|
CLICK HERE |
| 1942 |
National Cancer Institute |
Html |
es |
Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica. |
| French-American-British Cooperative Leukaemia | 0.312371 |
| leucemia mieloide | 0.341853 |
| myelomonocytic leukaemia | 0.397359 |
| myelomonocytic leukemia with | 0.326213 |
| platelet-derived growth factor | 0.354049 |
| with juvenile chronic | 0.315892 |
| Arber DA | 0.312178 |
| health organization classification | 0.3281 |
| Leukemia Group | 0.315441 |
| genes platelet-derived growth | 0.312347 |
| with juvenile | 0.340061 |
| chronic myeloid leukemia | 0.336615 |
| myelomonocytic leukemia | 0.944712 |
| leucemia mielomonocÃtica | 0.387953 |
| chronic myelomonocytic leukemia | 0.819447 |
| differentiating myelomonocytic leukemia | 0.320578 |
| Beran M | 0.312167 |
| World Health Organization | 0.355665 |
| neoplasias mielodisplásicas | 0.314258 |
| stem cell transplantation | 0.313202 |
| chronic myelogenous leukemia | 0.364294 |
| Germing U | 0.362762 |
| myeloproliferative disorders | 0.313394 |
| cases with chronic | 0.311538 |
| Leuk Lymphoma | 0.332534 |
|
| myelomonocytic leukemia from | 0.33992 |
| chronic myelomonocytic leukaemia | 0.386185 |
| juvenile chronic myelogenous | 0.347073 |
| marrow transplantation | 0.341155 |
| Organización Mundial | 0.317633 |
| chronic myeloid | 0.357031 |
| Differentiating juvenile myelomonocytic | 0.319715 |
| myeloid neoplasms | 0.336696 |
| bone marrow transplantation | 0.325127 |
| Bennett JM | 0.319603 |
| cromosoma filadelfia | 0.337822 |
| recuento plaquetario | 0.325577 |
| juvenile myelomonocytic leukaemia | 0.339361 |
| juvenile myelomonocytic leukemia | 0.545157 |
| chronic myeloid leukaemias | 0.320258 |
| Clin Oncol | 0.32115 |
| Orazi A | 0.343564 |
| Cooperative Leukaemia Group | 0.311788 |
| atypical chronic | 0.319445 |
| caracterÃsticas clÃnicas | 0.316309 |
| trastornos mieloides | 0.311632 |
| leucemia mieloide aguda | 0.316238 |
| with chronic myelomonocytic | 0.340508 |
| Emanuel PD | 0.350668 |
|
CLICK HERE |
| 1946 |
National Cancer Institute |
Html |
es |
Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma. |
| glándula tiroides | 0.633074 |
| posibles efectos tardÃos | 0.641796 |
| siguientes procedimientos | 0.632822 |
| células madre | 0.931788 |
| gen alk | 0.612181 |
| siguientes especialistas | 0.624871 |
| yodo 131-mibg | 0.744725 |
| vÃa oral | 0.649411 |
| rayos x | 0.630232 |
| enlace drugs approved | 0.631928 |
| estadios 2A | 0.624814 |
| niño ayuda | 0.632627 |
| ondas sonoras | 0.629873 |
| riesgo intermedio | 0.674697 |
| efectos tardÃos | 0.896983 |
| cáncer.ampliar aspiración | 0.633221 |
|
| National Cancer Institute | 0.612675 |
| IRMN).Ampliar Imágenes | 0.62564 |
| siguientes tratamientos | 0.624353 |
| menor producción | 0.628805 |
| Instituto Nacional | 0.623964 |
| PDQ Tratamiento | 0.634123 |
| determinados cambios | 0.611022 |
| alta potencia | 0.625499 |
| presente sección | 0.614217 |
| nuevos tipos | 0.61878 |
| sistema nervioso central | 0.655496 |
| Physician Data Query | 0.650241 |
| siguientes pruebas | 0.680017 |
| siguientes estadios | 0.629707 |
| siguientes trastornos | 0.624626 |
|
CLICK HERE |
| 2011 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| lung cancer screening | 0.491865 |
| Berg CD | 0.308884 |
| UK Lung Cancer | 0.309828 |
| Cooperative Early Lung | 0.306877 |
| Lung Cancer Study | 0.310626 |
| lung cancer | 0.996403 |
| Reduced lung-cancer mortality | 0.308509 |
| American Cancer Society | 0.314872 |
| Sloan-Kettering Lung Study | 0.306329 |
| Extended lung | 0.305748 |
| lung-cancer screening | 0.305282 |
| Lung Screening Trial | 0.34779 |
| Preventive Services Task | 0.315666 |
| early lung cancer | 0.370281 |
| Cancer Res | 0.308506 |
| screening results | 0.305543 |
| exámenes detección | 0.3124 |
| Screening Trial | 0.41076 |
| lung-cancer mortality with | 0.308638 |
| Randomized Danish Lung | 0.306065 |
| CT screening | 0.322848 |
| Natl Cancer Inst | 0.348878 |
| small lung | 0.309116 |
| Lung Cancer Risk | 0.310447 |
| from baseline screening | 0.305357 |
|
| More lung | 0.305626 |
| Screening Trial with | 0.311542 |
| early stage lung | 0.306471 |
| Is curable lung | 0.306471 |
| cytologic screening | 0.312546 |
| Hocking WG | 0.305973 |
| Hopkins Lung Project | 0.306129 |
| CT screening according | 0.305575 |
| Danish Lung Cancer | 0.338861 |
| Lung Cancer Action | 0.32014 |
| randomised danish lung | 0.306155 |
| National Lung Screening | 0.345051 |
| Intern Med | 0.314222 |
| lung cancer detection | 0.362796 |
| Services Task Force | 0.31539 |
| Randomized Lung Cancer | 0.310797 |
| from semi-annual screening | 0.30542 |
| PLCO Cancer Screening | 0.310194 |
| Mayo Lung Project | 0.341943 |
| lung cancers detected | 0.306094 |
| Memorial Sloan-Kettering | 0.306282 |
| Cancer Action Project | 0.310925 |
| Lung Project revisited | 0.306785 |
| Cancer Screening Trial | 0.390805 |
|
CLICK HERE |
| 2064 |
National Cancer Institute |
Html |
es |
Exposición al asbesto y el riesgo de cáncer |
Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información. |
| técnicos profesionales automotrices | 0.5421 |
| gen bap1 | 0.530949 |
| que familiares de trabajadores | 0.533144 |
| normas descritas | 0.532666 |
| largo plazo | 0.526581 |
| Protección Ambiental | 0.672505 |
| World Trade Center | 0.546459 |
| principal dependencia | 0.532045 |
| Ground Zero | 0.529197 |
| derrames pleurales benignos | 0.558277 |
| Salud Ocupacional | 0.584399 |
| asbesto crisótilo | 0.987156 |
| trabajadores portuarios | 0.606054 |
| Instituto Nacional | 0.563708 |
| menores riesgos | 0.533274 |
| Trabajo de EE | 0.535904 |
| Employment Standards Administration | 0.548898 |
| titulado current best practices | 0.543841 |
| Mine Safety | 0.535362 |
| sustancias tóxicas | 0.635631 |
| siglo xix | 0.53032 |
| distintos tipos | 0.525229 |
| Estados Unidos | 0.992615 |
| automotriz usa | 0.531695 |
| Public Affairs | 0.529764 |
|
| serios problemas | 0.529441 |
| Environmental Protection Agency | 0.815767 |
| lÃnea telefónica tsca | 0.556811 |
| Preventing Asbestos Exposure | 0.544747 |
| Product Safety Commission | 0.67091 |
| Information Division | 0.52746 |
| Occupational Safety | 0.586355 |
| asbesto causa | 0.952053 |
| cuánto tiempo | 0.527545 |
| en la mucosidad | 0.531534 |
| a las personas | 0.529484 |
| posibles peligros | 0.5266 |
| Health Administration | 0.652906 |
| Consumer Product Safety | 0.672282 |
| causa dificultad | 0.530297 |
| sumamente bajo. Los fabricantes | 0.528798 |
| mejores prácticas | 0.574094 |
| Clutch Repair Workers | 0.544379 |
| Veterans Affairs | 0.528386 |
| Torres Gemelas | 0.52642 |
| Compensation Programs | 0.5287 |
| Disease Registry | 0.526245 |
| Toxic Substances | 0.526971 |
| Segunda Guerra Mundial | 0.550565 |
|
CLICK HERE |
| 3444 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe. |
| Ramadas K | 0.326456 |
| Sankaranarayanan R | 0.337876 |
| accessed march | 0.331249 |
| Zhang L | 0.310727 |
| Clinical Preventive Services | 0.308765 |
| Interim results from | 0.307724 |
| Sin embargo | 0.381657 |
| Kerr AR | 0.312561 |
| American Cancer Society | 0.427439 |
| Early findings from | 0.308051 |
| CA Cancer | 0.323169 |
| cluster randomized controlled | 0.308479 |
| oral pre-malignant | 0.326412 |
| oral cancer | 0.913191 |
| Preventive Services Task | 0.376173 |
| Instituto Nacional | 0.317765 |
| Cancer Res | 0.323621 |
| Human papillomavirus infection | 0.307515 |
| PDQ Exámenes | 0.32226 |
| oral cancer screening | 0.566684 |
| Estados Unidos | 0.310609 |
| Morton TH Jr | 0.307383 |
| Morton TH | 0.311837 |
| Epstein JB | 0.323025 |
| Database Syst Rev | 0.307163 |
|
| visual screening | 0.315772 |
| screening with | 0.315479 |
| upper aerodigestive tract | 0.307566 |
| SEER Cancer Statistics | 0.324889 |
| Cancer Society guidelines | 0.325639 |
| Trivandrum Oral Cancer | 0.343561 |
| carcinoma versus lesiones | 0.311231 |
| Jacob BJ | 0.31089 |
| potentially malignant disorders | 0.308445 |
| Cancer Facts | 0.324242 |
| Long term effect | 0.3078 |
| adjacent to clinically | 0.307949 |
| Oral Oncol | 0.526329 |
| oral verrucous | 0.325426 |
| National Cancer Institute | 0.351683 |
| center grapples with | 0.307601 |
| Oral Pathol Med | 0.361585 |
| Screening Study Group | 0.316915 |
| Am Dent Assoc | 0.308416 |
| Services Task Force | 0.375429 |
| Fluorescence visualization detection | 0.308258 |
| detección versus atención | 0.319469 |
| Brief Evidence Update | 0.307856 |
| Poh CF | 0.312257 |
|
CLICK HERE |
| 3460 |
National Cancer Institute |
Html |
es |
Coenzima Q10 (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer. |
| Natl Acad Sci | 0.506232 |
| animal models | 0.503048 |
| Lockwood K | 0.522246 |
| Friend leukemia virus | 0.50335 |
| Mol Aspects Med | 0.525442 |
| Prog Drug Res | 0.505422 |
| Exp Clin Res | 0.507107 |
| Ernster L | 0.506157 |
| Clin Investig | 0.504327 |
| vitamina q10 | 0.508703 |
| vitamin q10 | 0.549224 |
| Health Syst Pharm | 0.503499 |
| Chem Pathol Pharmacol | 0.515808 |
| Bliznakov EG | 0.512562 |
| Hanioka T | 0.504235 |
| coenzyme q10 | 0.845306 |
| with vitamin q10 | 0.522905 |
| reticuloendothelial system upon | 0.50329 |
| Res Commun Chem | 0.525595 |
| coenzima q10 | 0.990386 |
| Nylander M | 0.503126 |
| system upon stimulation | 0.503357 |
| coenzima q.10 | 0.50372 |
| Coenzyme Q10 administration | 0.515239 |
| patients with | 0.52239 |
|
| Clinical Aspects | 0.506167 |
| Folkers K | 0.720923 |
| patients treated with | 0.503528 |
| Osterborg A | 0.503093 |
| coenzima q10 resumen | 0.509859 |
| Commun Chem Pathol | 0.52121 |
| Moesgaard S | 0.509545 |
| Biophys Res Commun | 0.66246 |
| Chemother Rep | 0.503476 |
| Nordenbrand K | 0.502764 |
| Proc Natl Acad | 0.506461 |
| Apparent partial remission | 0.503092 |
| Biochem Biophys Res | 0.653978 |
| with nutritional antioxidants | 0.504649 |
| coenzima q10 ayuda | 0.51293 |
| Drugs Exp Clin | 0.50459 |
| conzima q10 | 0.506965 |
| Overvad K | 0.504381 |
| Clin Nutr | 0.503026 |
| serious deficiency | 0.503488 |
| coenzyme q10 concentrations | 0.523415 |
| radicales libres | 0.504036 |
| essential fatty acids | 0.503269 |
| Yamashita S | 0.503124 |
|
CLICK HERE |
| 15639 |
National Cancer Institute |
Html |
null |
Grants |
Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others. |
|
|
CLICK HERE |
| 16842 |
National Cancer Institute |
Html |
en |
Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research |
The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here. |
| predoctoral fellows | 0.736483 |
| cancer nanobiotechnology | 0.632531 |
| optimal treatment | 0.545276 |
| Johns Hopkins University | 0.729715 |
| journal club | 0.539106 |
| novel cancer diagnostics | 0.713403 |
| program fosters | 0.562779 |
| steady state number | 0.670018 |
| epigenetic markers | 0.560601 |
| tumor boards | 0.538166 |
| NTCR program | 0.576419 |
| new frontier | 0.564875 |
| individual patient | 0.643505 |
| engineering/physics discipline | 0.563571 |
| physical sciences-oncology center | 0.676488 |
| lab course | 0.540911 |
| new modalities | 0.563 |
| cellular / cancer | 0.59221 |
| Johns Hopkins Institute | 0.669855 |
| dedicated annual symposium | 0.651728 |
| experimental facilities | 0.538368 |
| Vivo Cellular | 0.548936 |
| Molecular Imaging Center | 0.688968 |
| black-box input-output techniques | 0.710638 |
|
| scientific exploration | 0.554225 |
| clinical resources | 0.5443 |
| human diseases | 0.555299 |
| cancer cell functions | 0.720912 |
| clinical conferences | 0.540551 |
| high-throughput diagnostic tools | 0.682779 |
| non-viral delivery systems | 0.686087 |
| unique educational resources | 0.657197 |
| postdoctoral fellows | 0.715577 |
| Principal Investigator | 0.564913 |
| therapeutic tools | 0.551025 |
| Pancreatic Cancer Center | 0.731915 |
| Ludwick Center | 0.581555 |
| NTCR trainees | 0.59515 |
| cancer nanotechnology excellence | 0.742492 |
| outstanding trainees | 0.578764 |
| disease phenotype | 0.55677 |
| Comprehensive Cancer Center | 0.727928 |
| Cancer Genetics | 0.585039 |
| NTCR fellows | 0.742981 |
| engineer novel drug/antibody/siRNA | 0.668859 |
| human cancers | 0.551276 |
| core courses | 0.541397 |
| Training Focus | 0.565904 |
|
CLICK HERE |